Literature DB >> 30362148

Serum Hepatitis B Virus RNA: A New Potential Biomarker for Chronic Hepatitis B Virus Infection.

Shi Liu1, Bin Zhou1,2, Juan D Valdes2, Jian Sun1, Haitao Guo2.   

Abstract

Chronic hepatitis B infection is one of the major etiological causes of liver failure, cirrhosis, and hepatocellular carcinoma (HCC) worldwide. This condition cannot be completely cured by currently available drugs due to the persistent existence of hepatitis B virus (HBV) covalently closed circular DNA (cccDNA), the bona fide transcription template for HBV RNAs, in infected hepatocytes. Because quantifying cccDNA per se requires an invasive procedure, serum biomarkers reflecting intrahepatic cccDNA activity are warranted. Recently, a growing body of research suggests that the circulating HBV RNA may serve as a serum biomarker for HBV infection, treatment, and prognosis. In order to delineate the molecular and clinical characteristics of serum HBV RNA, we systematically reviewed the available literature on serum HBV RNA dating back to the early 1990s. In this review, we summarize the reported serum HBV RNA quantification methods and discuss the potential HBV RNA species in patient serum. We also compare the reported correlations of serum HBV RNA with other serological markers, including HBV DNA, hepatitis B surface antigen, e antigen, and core-related antigen, as well as their correlations with intrahepatic cccDNA, to assess their potential in clinical applications. Future directions for serum HBV RNA research are also discussed.
© 2018 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30362148      PMCID: PMC6438723          DOI: 10.1002/hep.30325

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  60 in total

1.  Genomic DNA double-strand breaks are targets for hepadnaviral DNA integration.

Authors:  Colin A Bill; Jesse Summers
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-16       Impact factor: 11.205

2.  Circulating hepatitis B virus nucleic acids in chronic infection : representation of differently polyadenylated viral transcripts during progression to nonreplicative stages.

Authors:  Q Su; S F Wang; T E Chang; R Breitkreutz; H Hennig; K Takegoshi; L Edler; C H Schröder
Journal:  Clin Cancer Res       Date:  2001-07       Impact factor: 12.531

3.  Diversity of hepatitis B virus X gene-related transcripts in hepatocellular carcinoma: a novel polyadenylation site on viral DNA.

Authors:  C Hilger; I Velhagen; H Zentgraf; C H Schröder
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

4.  Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids.

Authors:  Stefan F Wieland; Angelina Eustaquio; Christina Whitten-Bauer; Bryan Boyd; Francis V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-01       Impact factor: 11.205

5.  Hepatitis B virus particle formation in the absence of pregenomic RNA and reverse transcriptase.

Authors:  Wiebke Schormann; Anke Kraft; Dirk Ponsel; Volker Bruss
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

6.  Truncated hepatitis B virus RNA in human hepatocellular carcinoma: its representation in patients with advancing age.

Authors:  A Kairat; W Beerheide; G Zhou; Z Y Tang; L Edler; C H Schröder
Journal:  Intervirology       Date:  1999       Impact factor: 1.763

7.  Hepatitis B virus nucleic acids circulating in the blood: distinct patterns in HBs carriers with hepatocellular carcinoma.

Authors:  R Breitkreutz; W Zhang; M Lee; A Hoffmann; M Tokus; Q Su; C H Schröder
Journal:  Ann N Y Acad Sci       Date:  2001-09       Impact factor: 5.691

8.  Patterns of circulating hepatitis B virus serum nucleic acids during lamivudine therapy.

Authors:  Hans Jörg Hacker; Wei Zhang; Mehmet Tokus; Thomas Bock; Claus H Schröder
Journal:  Ann N Y Acad Sci       Date:  2004-06       Impact factor: 5.691

9.  Patterns of circulating hepatitis B virus serum nucleic acids during lamivudine therapy.

Authors:  Wei Zhang; Hans Jörg Hacker; Mehmet Tokus; Thomas Bock; Claus H Schröder
Journal:  J Med Virol       Date:  2003-09       Impact factor: 2.327

10.  Absence of free core antigen in anti-HBc negative viremic hepatitis B carriers.

Authors:  C Possehl; R Repp; K H Heermann; E Korec; A Uy; W H Gerlich
Journal:  Arch Virol Suppl       Date:  1992
View more
  41 in total

1.  Serum HBV RNA composition dynamics as a marker for intrahepatic HBV cccDNA turnover.

Authors:  Xupeng Hong; Jianming Hu
Journal:  J Med Virol       Date:  2020-06-02       Impact factor: 2.327

2.  Hepatitis B Virus Precore Protein p22 Inhibits Alpha Interferon Signaling by Blocking STAT Nuclear Translocation.

Authors:  Bidisha Mitra; Jinyu Wang; Elena S Kim; Richeng Mao; Minhui Dong; Yuanjie Liu; Jiming Zhang; Haitao Guo
Journal:  J Virol       Date:  2019-06-14       Impact factor: 5.103

3.  Change of Cytokines in Chronic Hepatitis B Patients and HBeAg are Positively Correlated with HBV RNA, Based on Real-world Study.

Authors:  Qiqi Zhang; Hui Huang; Aijun Sun; Chunyan Liu; Zhidong Wang; Feifan Shi; Wei Duan; Xueying Sun; Qi Wang; Ping Sun; Chunwen Pu; Yong Zhang
Journal:  J Clin Transl Hepatol       Date:  2021-09-18

4.  KASL clinical practice guidelines for management of chronic hepatitis B.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2022-04-01

Review 5.  Revisiting Hepatitis B Virus: Challenges of Curative Therapies.

Authors:  Jianming Hu; Ulrike Protzer; Aleem Siddiqui
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

6.  Assessment of hepatitis B virus pregenomic RNA in high and low viremic chronic hepatitis B patients.

Authors:  Aymen Farid Elshayeb; Mohamed Gamal Abdrabu; Sara Lotfy Asar; Mohamed Adel Abdelaziz; Hossam Abuelkheir
Journal:  Clin Exp Hepatol       Date:  2021-03-25

Review 7.  Should We Treat Immune Tolerant Chronic Hepatitis B? Lessons from Asia.

Authors:  Madhumita Premkumar; Yogesh K Chawla
Journal:  J Clin Exp Hepatol       Date:  2021-08-27

8.  RNA Helicase DDX17 Inhibits Hepatitis B Virus Replication by Blocking Viral Pregenomic RNA Encapsidation.

Authors:  Richeng Mao; Minhui Dong; Zhongliang Shen; Hu Zhang; Yuanjie Liu; Dawei Cai; Bidisha Mitra; Jiming Zhang; Haitao Guo
Journal:  J Virol       Date:  2021-09-09       Impact factor: 5.103

9.  The Prognostic Role of On-Treatment Liver Stiffness for Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B.

Authors:  Hye Won Lee; Hyun Woong Lee; Jae Seung Lee; Yun Ho Roh; Hyein Lee; Seung Up Kim; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Beom Kyung Kim
Journal:  J Hepatocell Carcinoma       Date:  2021-05-25

10.  Clinical Implications of Serum Hepatitis B Virus Pregenomic RNA Kinetics in Chronic Hepatitis B Patients Receiving Antiviral Treatment and Those Achieving HBsAg Loss.

Authors:  I-Chin Wu; Wen-Chun Liu; Yen-Cheng Chiu; Hung-Chih Chiu; Pin-Nan Cheng; Ting-Tsung Chang
Journal:  Microorganisms       Date:  2021-05-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.